Cargando…

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment

BACKGROUND: To compare the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment (PED) in age-related macular degeneration. METHODS: Eighty-three eyes of 83 patients diagnosed with type 1 macular neovascularization were included and retrospectively analysed using multim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukai, Ryo, Matsumoto, Hidetaka, Nagai, Kazuki, Akiyama, Hideo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520796/ https://www.ncbi.nlm.nih.gov/pubmed/36175862 http://dx.doi.org/10.1186/s12886-022-02617-2

Ejemplares similares

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration
por: Mukai, Ryo, et al.
Publicado: (2021)

Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection
por: Chakraborty, Somnath, et al.
Publicado: (2023)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2021)

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy
por: Nam, Seung Wan, et al.
Publicado: (2022)

Occlusion of a Vortex Vein After Treatment With Half-Fluence Photodynamic Therapy Combined With Intravitreal Aflibercept Injection for Pachychoroid Neovasculopathy
por: Yamada, Chizu, et al.
Publicado: (2022)

A Case Of Ipilimumab-Induced Unusual Serous Retinal Detachment In Bilateral Eyes
por: Miyakubo, Tomoko, et al.
Publicado: (2019)

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue()
por: Davoudi, Samaneh, et al.
Publicado: (2021)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment
por: Nagai, Norihiro, et al.
Publicado: (2016)

Retinal pigment epithelial tear following intravitreal injection of brolucizumab
por: Ashkenazy, Noy, et al.
Publicado: (2021)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
por: Bilgic, Alper, et al.
Publicado: (2021)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration
por: Rispoli, Marco, et al.
Publicado: (2021)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
por: Tyagi, Pallavi, et al.
Publicado: (2018)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

A hyporeflective space between hyperreflective materials in pigment epithelial detachment and Bruch’s membrane in neovascular age-related macular degeneration
por: Mukai, Ryo, et al.
Publicado: (2014)

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Remodeling of macular vortex veins in pachychoroid neovasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2019)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Assessment of macular function in patients with non-vascularized pigment epithelial detachment
por: Kitano, Marie, et al.
Publicado: (2021)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study
por: Chan, Clement K., et al.
Publicado: (2020)

Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis
por: Sun, Zuhua, et al.
Publicado: (2023)

Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model
por: Schubert, William, et al.
Publicado: (2022)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
por: Arias, Luis
Publicado: (2010)

Isolated Multiple Pigment Epithelial Detachments with Unknown Cause
por: Karatepe Hashas, Arzu Seyhan, et al.
Publicado: (2014)

Full-thickness macular hole with pigment epithelial detachment
por: Narnaware, Shilpi H, et al.
Publicado: (2020)

De-novo multilayering in fibrovascular pigment epithelial detachment
por: Soman, Manoj, et al.
Publicado: (2021)

Drusenoid Pigment Epithelial Detachment: Genetic and Clinical Characteristics
por: Shijo, Taiyo, et al.
Publicado: (2021)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ojq3eu4atkbvlgk7rdpukkq6qd